MARKET NEWS

STRATA Skin Sciences Announces Completion of a Clinical Study
Orphazyme Reports Encouraging Arimoclomol Clinical Trial Top-Line Data
Melinta Therapeutics & Menarini Group Enter Commercial Agreement
Dragonfly Therapeutics Announces New Multi-Target Collaboration With Merck
Hitachi Chemical Advanced Therapeutics Solutions Signs 3-Year Agreement With GSK
Arzeda & BP Sign Collaborative Joint Development Agreement

  FEATURED EDITORIAL

  COMPANY PROFILE

 

Hovione has over 55 year of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA-inspected sites in the US, Ireland, Portugal, and China and development laboratories in Portugal and the US, Hovione provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds. Hovione employs 1,900 people worldwide and has more than 1300m3 of flexible production capacity. Click here for more.

  EXCLUSIVE ONLINE CONTENT

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

Like all pharmaceuticals, ophthalmic preparations are subject to microbiological contamination. Both ophthalmic solutions used for diagnostic and therapeutic purposes have been found to be contaminated by pathogenic bacteria with reported rates as high as 70%, associated with severe ocular infections such as keratitis and endophthalmitis.

Evonik Launches Advanced Combination Polymer; Sets New Benchmark for Enteric Coatings

Evonik Launches Advanced Combination Polymer; Sets New Benchmark for Enteric Coatings

Evonik, a global leader for functional excipients used in oral solid dosage forms, recently announced the launch of an advanced combination polymer for enteric coatings.

Aptar Pharma Launches New Portable & Ready-to-Use Upper Respiratory Drug Delivery Solution

Aptar Pharma Launches New Portable & Ready-to-Use Upper Respiratory Drug Delivery Solution

Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care.

Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study

Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study

Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 17 – Bioavailability
October 24 – Capsules